Table 2 Clinical and laboratory features of patients in the LUMINA cohort as a function of the occurrence of hypertension any time after enrollment into the LUMINA cohort.
| Variables | Hypertension | p Value | |
|---|---|---|---|
| Present, (n = 136) | Absent, (n = 243) | ||
| Acute onset type (%) | 84 | 87 | 0.285 |
| Mean (SD) follow‐up time, (years) | 2.6 (2.4) | 3.0 (2.5) | 0.112 |
| Mean (SD), total disease duration, (years) | 4.1 (2.9) | 4.2 (3.0) | 0.716 |
| Mean (SD) disease activity* | 8.0 (3.8) | 7.1 (4.2) | 0.046 |
| Mean (SD) damage accrual† | 0.6 (0.9) | 0.5 (1.0) | 0.337 |
| Renal involvement (%) | 62 | 30 | <0.001 |
| Diabetes mellitus (%) | 6 | 2 | 0.032 |
| Body mass index (kg/m2) | 26.4 (4.8) | 25.3 (4.5) | 0.026 |
| Mean (SD) baseline serum creatinine, (mg/dl) | 0.7 (0.4) | 0.7 (0.3) | 0.307 |
| Mean (SD) LDL cholesterol, (mg/dl) | 99 (38) | 94 (39) | 0.193 |
| LDL cholesterol >130 mg/dl (%) | 20 | 12 | 0.061 |
| Mean (SD) triglyceride, (mg/dl) | 133 (69) | 122 (66) | 0.152 |
| Mean (SD) high sensitivity‐ C reactive protein | 13.3 (21.9) | 12.2 (30.3) | 0.712 |
| Anti‐dsDNA antibodies (%) | 57 | 47 | 0.070 |
| Antiphospholipid antibodies (%) | 34 | 22 | 0.014 |
| Low‐dose aspirin use (%) | 11 | 17 | 0.102 |
| Use of NSAID (%) | 56 | 57 | 0.864 |
| Hydroxychloroquine use (%) | 85 | 86 | 0.762 |
| Glucocorticoid use (%) | 96 | 89 | 0.035 |
| Weighted average glucocorticoid dose (in mg of prednisone/day) | 7.1 (10.3) | 6.7 (11.7) | 0.738 |
LDL, low‐density lipoprotein; NSAID, non‐steroidal anti‐inflammatory drugs.
*As per the Systemic Lupus Activity Measure‐Revised over time, scores from the renal domain and hypertension were excluded.
†As per the Systemic Lupus International Collaborating Clinics Damage Index, scores from the renal domain were excluded.